Skip to main content
L

Luoxin Pharmaceuticals Group Stock Co., Ltd. — Investor Relations & Filings

Ticker · 002793 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,588 across all filing types
Latest filing 2026-04-22 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002793

About Luoxin Pharmaceuticals Group Stock Co., Ltd.

https://www.luoxin.cn

Luoxin Pharmaceuticals Group Stock Co., Ltd. focuses on the research, development, manufacturing, and distribution of diverse medicinal products. The company specializes in therapeutic areas including digestive health, respiratory medicine, anti-infectives, and oncology. Its portfolio includes various formulations such as injections, tablets, and capsules, with a notable emphasis on proton pump inhibitors and respiratory treatments. Luoxin operates a vertically integrated model, producing both active pharmaceutical ingredients (APIs) and finished dosage forms. The organization emphasizes innovation through dedicated R&D facilities to develop high-quality healthcare solutions. Its operations are supported by a comprehensive supply chain and manufacturing infrastructure designed to adhere to international quality standards, serving broad market segments with a focus on clinical efficacy and patient accessibility.

Recent filings

Filing Released Lang Actions
2025年度独立董事述职报告-许霞
Governance Information Classification · 1% confidence The document is a 2025 annual performance report (“述职报告”) by an independent director detailing her duties, meeting attendance, oversight work, and compliance with governance rules. This is not a financial results announcement (ER), not an earnings call transcript (CT), nor an audit report (AR). It is a corporate governance disclosure concerning board practices and independent director duties. The closest matching category is Governance Information (CGR).
2026-04-22 Chinese
关于变更会计政策的公告
Regulatory Filings Classification · 1% confidence The document is a formal public announcement regarding a change in accounting policy by the board of Luoxin Pharmaceutical Group Co., Ltd. It does not contain full-year or interim financial statements, detailed management analysis, or audit opinions, nor is it an invitation or proxy material. Instead, it is a regulatory disclosure notice of an accounting policy change under Chinese GAAP. This type of announcement falls outside specific categories like Annual Report (10-K), Audit Report (AR), or Management Discussion & Analysis (MDA) and is best classified in the general regulatory filings bucket.
2026-04-22 Chinese
第六届董事会第四次会议决议公告
Board/Management Information Classification · 1% confidence The document is titled “第六届董事会第四次会议决议公告” and details the resolutions passed at the board meeting, including approvals of annual work reports, internal control reports, ESG report, profit distribution, auditor reappointment, and the appointment of an internal audit head. This is a corporate announcement of board meeting resolutions and a management appointment. It fits the “Board/Management Information” category (MANG), which covers announcements related to board and senior management matters.
2026-04-22 Chinese
非经营性资金占用及其他关联资金往来情况的专项审计说明
Audit Report / Information Classification · 1% confidence The document is a detailed standalone special audit report (“专项审计说明”) on non-operating fund occupation and related party transactions for the 2025 financial year, including auditor’s opinion, scope, and audit conclusion, together with attachments such as practice certificates. It is not a short notice but the actual audit report itself. Therefore it fits the definition of an Audit Report / Information (AR).
2026-04-22 Chinese
罗欣药业集团股份有限公司2026年第二次临时股东会之法律意见书
Regulatory Filings Classification · 1% confidence The document is a legal opinion letter provided by a law firm (King & Wood) on the convening, attendance, procedures, and voting results of Luoxin Pharma’s 2026 extraordinary shareholders’ meeting. It is not a financial report (10-K, IR), not an earnings release, not a proxy solicitation statement (PSI), nor a straightforward voting results announcement (DVA) by the company—it goes well beyond mere vote counts, offering legal validation of the meeting’s procedures. It also is not a litigation update. There is no standalone filing category for a “legal opinion letter,” so this miscellaneous regulatory submission falls into the fallback Regulatory Filings category.
2026-04-22 Chinese
关于2025年度计提资产减值准备及确认公允价值变动损益的公告
Regulatory Filings Classification · 1% confidence The document is a standalone corporate announcement by 罗欣药业集团股份有限公司 detailing its 2025年度 asset impairment provisions and fair value change gains and losses. It is not a full Annual Report (10-K), Earnings Release (ER), Interim Report (IR), or any of the specialized categories (e.g., board changes, dividends, share issues). Instead, it is a mandatory regulatory disclosure of specific accounting adjustments, fitting the fallback category of a general regulatory filing.
2026-04-22 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.